Compounds > ibuprofen
Page last updated: 2024-10-28

ibuprofen and Genetic Predisposition

ibuprofen has been researched along with Genetic Predisposition in 9 studies

Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine

Research Excerpts

ExcerptRelevanceReference
"Ibuprofen may inhibit lung cancer progression."2.73Factors associated with human small aggressive non small cell lung cancer. ( Berg, CD; Church, TR; Freedman, MT; Hocking, WG; Hu, P; Kvale, PA; Oken, MM; Prorok, PC; Ragard, LR; Riley, TL; Tammemagi, CM, 2007)
"Interindividual variability in drug metabolism is an important cause of adverse drug reactions and variability in drug efficiency."2.53How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity. ( Bilić, I; Božina, N; Dimovski, A; Domjanović, IK; Krasniqi, V, 2016)
"Although the diagnosis and treatment of slipped capital femoral epiphysis have been well described, the search for its cause and a method of early identification continues."1.37Three cases of slipped capital femoral epiphysis in one family. ( Leu, D; Papp, DF; Sargent, MC; Skelley, NW, 2011)
"A population-based study of 750 rectal cancer cases with interview and tumor DNA were compared to 1,205 population-based controls."1.35Tumor markers and rectal cancer: support for an inflammation-related pathway. ( Caan, BJ; Herrick, J; Samowitz, W; Slattery, ML; Wolff, RK, 2009)
"Overall, prostate cancer was not related to AMACR gene variants; however, risks for prostate cancer were significantly reduced among regular ibuprofen users who carried allele variants at four nsSNP loci (M9V, D175G, S201L, and K277E; all P(trend) < 0."1.34Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer. ( Daugherty, SE; Fallin, MD; Hayes, RB; Huang, WY; Isaacs, WB; Pfeiffer, RM; Platz, EA; Reding, D; Shugart, YY; Welch, R, 2007)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lewis, TR1
Shelton, EL1
Van Driest, SL1
Kannankeril, PJ1
Reese, J1
Caimmi, SM1
Manca, E1
Caimmi, D1
Marseglia, GL1
Demoly, P1
Lu, W1
Cheng, F1
Jiang, J1
Zhang, C1
Deng, X1
Xu, Z1
Zou, S1
Shen, X1
Tang, Y1
Huang, J1
Krasniqi, V1
Dimovski, A1
Domjanović, IK1
Bilić, I1
Božina, N1
Slattery, ML1
Wolff, RK1
Herrick, J1
Caan, BJ1
Samowitz, W1
Skelley, NW1
Papp, DF1
Leu, D1
Sargent, MC1
Daugherty, SE1
Shugart, YY1
Platz, EA1
Fallin, MD1
Isaacs, WB1
Pfeiffer, RM1
Welch, R1
Huang, WY1
Reding, D1
Hayes, RB1
Pilotto, A1
Seripa, D1
Franceschi, M1
Scarcelli, C1
Colaizzo, D1
Grandone, E1
Niro, V1
Andriulli, A1
Leandro, G1
Di Mario, F1
Dallapiccola, B1
Tammemagi, CM1
Freedman, MT1
Church, TR1
Oken, MM1
Hocking, WG1
Kvale, PA1
Hu, P1
Riley, TL1
Ragard, LR1
Prorok, PC1
Berg, CD1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial[NCT00002540]76,685 participants (Actual)Interventional1993-11-16Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Death Rates From All Causes

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009.

InterventionDeaths per 10,000 PY (Number)
Control166.6
Prostate Screening160.5

Deaths From All Causes

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009.

InterventionParticipants (Number)
Control7089
Prostate Screening6855

Prostate Cancer Death Rates

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

InterventionDeaths per 10,000 PY (Number)
Control3.4
Prostate Screening3.7

Prostate Cancer Deaths

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

InterventionParticipants (Number)
Control145
Prostate Screening158

Prostate Cancer Incidence

Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

InterventionParticipants (Number)
Control3815
Prostate Screening4250

Prostate Cancer Incidence Rates

Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

InterventionDiagnoses per 10,000 PY (Number)
Control97.1
Prostate Screening108.4

Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test

Number of positive screens with complications (NCT00002540)
Timeframe: One year from screening examination

InterventionPositive screens w/ complications (Number)
When DE Led to Prostate Cancer DiagnosisWhen DE Did Not Lead to Prostate Cancer Diagnosis
Prostate Screening901124

T0 (Baseline) DRE Screening Results

Digital Rectal Examination (DRE) result. (NCT00002540)
Timeframe: T0 (at study entry)

InterventionParticipants (Number)
NegativePositiveInadequate screen
Prostate Screening3045624811192

T0 (Baseline) PSA Screening Results

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T0 (at study entry)

InterventionParticipants (Number)
Negative (<=4 ng/mL)Positive (> 4 ng/mL)Inadequate screen
Prostate Screening31507271822

T1 DRE Screening Results

Digital Rectal Examination (DRE) result. (NCT00002540)
Timeframe: T1 (one year after entry)

InterventionParticipants (Number)
NegativePositiveInadequate screen
Prostate Screening293112237900

T1 PSA Screening Results

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T1 (one year after entry)

InterventionParticipants (Number)
Negative (<=4 ng/mL)Positive (> 4 ng/mL)Inadequate screen
Prostate Screening30159250227

T2 DRE Screening Results

Digital Rectal Examination (DRE) results (NCT00002540)
Timeframe: T2 (two years after entry)

InterventionParticipants (Number)
NegativePositiveInadequate screen
Prostate Screening283912327733

T2 PSA Screening Results

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T2 (two years after entry)

InterventionParticipants (Number)
NegativePositive (> 4 ng/mL)Inadequate screen
Prostate Screening29063259335

T3 DRE Screening Results

Digital Rectal examination (DRE) result (NCT00002540)
Timeframe: T3 (three years after entry)

InterventionParticipants (Number)
NegativePositiveInadequate screen
Prostate Screening271792317748

T3 PSA Screening Results

Prostate-Specific Antigen (PSA) result (NCT00002540)
Timeframe: T3 (three years after entry)

InterventionParticipants (Number)
Negative (<=4 ng/mL)Positive (> 4 ng/mL)Inadequate screen
Prostate Screening27814267643

T4 PSA Screening Result

Prostate-Specific Antigen (PSA) result (NCT00002540)
Timeframe: T4 (four years after entry)

InterventionParticipants (Number)
Negative (<=4 ng/mL)Positive (> 4 ng/mL)Inadequate screen
Prostate Screening20362179612

T5 PSA Screening Results

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T5 (five years after entry)

InterventionParticipants (Number)
Negative (<=4 ng/mL)Positive (> 4 ng/mL)Inadequate screen
Prostate Screening23560237714

Reviews

2 reviews available for ibuprofen and Genetic Predisposition

ArticleYear
Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.
    Seminars in fetal & neonatal medicine, 2018, Volume: 23, Issue:4

    Topics: Acetaminophen; Animals; Disease Models, Animal; Ductus Arteriosus, Patent; Genetic Predisposition to

2018
How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity.
    Arhiv za higijenu rada i toksikologiju, 2016, Volume: 67, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cytochrome P-450 CYP2C8; Cytochrome P-450 Enzyme System; Di

2016

Trials

1 trial available for ibuprofen and Genetic Predisposition

ArticleYear
Factors associated with human small aggressive non small cell lung cancer.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, Volume: 16, Issue:10

    Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Non-Small-Cell Lung; C

2007

Other Studies

6 other studies available for ibuprofen and Genetic Predisposition

ArticleYear
NSAID hypersensitivity in twins.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2014, Volume: 25, Issue:8

    Topics: Adolescent; Allergens; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; Celecoxib; Child; Ch

2014
FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach.
    Scientific reports, 2015, Jan-29, Volume: 5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Genetic Predisposit

2015
Tumor markers and rectal cancer: support for an inflammation-related pathway.
    International journal of cancer, 2009, Oct-01, Volume: 125, Issue:7

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Biomarkers, Tumor; Cali

2009
Three cases of slipped capital femoral epiphysis in one family.
    Orthopedics, 2011, Aug-08, Volume: 34, Issue:8

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Bone Screws; Child; Family Health; Female; Gene

2011
Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer.
    The Prostate, 2007, Oct-01, Volume: 67, Issue:14

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Chemoprevention; Genetic Marker

2007
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
    Gastroenterology, 2007, Volume: 133, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Cas

2007